MeiraGTx Holdings plc Operating Expenses
MeiraGTx Holdings plc (MGTX) reported Operating Expenses of $77.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- MeiraGTx Holdings plc operating expenses for the quarter ending 2026-06-30 was $77.01M, a 58.83% increase year-over-year.
- MeiraGTx Holdings plc operating expenses for the quarter ending 2026-03-31 was $41.11M, a 5.54% decline year-over-year.
- MeiraGTx Holdings plc operating expenses for the quarter ending 2025-12-31 was $48.89M, a 7.54% decline year-over-year.
- MeiraGTx Holdings plc operating expenses for the quarter ending 2025-09-30 was $46.46M, a 8.81% decline year-over-year.
- MeiraGTx Holdings plc operating expenses for fiscal 2025 was $187.36M, a 5.13% decline from fiscal 2024.
- MeiraGTx Holdings plc operating expenses for fiscal 2024 was $197.49M, a 30.72% increase from fiscal 2023.
- MeiraGTx Holdings plc operating expenses for fiscal 2023 was $151.08M, a 14.22% increase from fiscal 2022.
- MeiraGTx Holdings plc operating expenses for fiscal 2022 was $132.28M, a 19.75% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $77.01M 10-Q · filed 2026-08-13 | $118.12M 10-Q · filed 2026-08-13 | $167.01M derived: sum of 3 quarters · filed 2026-08-13 | $213.47M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $41.11M 10-Q · filed 2026-05-14 | $90.00M derived: sum of 2 quarters · filed 2026-05-14 | $136.46M derived: sum of 3 quarters · filed 2026-05-14 | $184.95M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $48.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $95.35M derived: sum of 2 quarters · filed 2026-03-30 | $143.84M derived: sum of 3 quarters · filed 2026-08-13 | $187.36M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $46.46M 10-Q · filed 2025-11-13 | $94.94M derived: sum of 2 quarters · filed 2026-08-13 | $138.47M 10-Q · filed 2025-11-13 | $191.35M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $48.48M 10-Q · filed 2026-08-13 | $92.01M 10-Q · filed 2026-08-13 | $144.89M derived: sum of 3 quarters · filed 2026-08-13 | $195.84M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $43.52M 10-Q · filed 2026-05-14 | $96.40M derived: sum of 2 quarters · filed 2026-05-14 | $147.35M derived: sum of 3 quarters · filed 2026-05-14 | $193.54M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $52.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $103.83M derived: sum of 2 quarters · filed 2026-03-30 | $150.02M derived: sum of 3 quarters · filed 2026-03-30 | $197.49M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $50.95M 10-Q · filed 2025-11-13 | $97.14M derived: sum of 2 quarters · filed 2025-11-13 | $144.61M 10-Q · filed 2025-11-13 | $190.41M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $46.19M 10-Q · filed 2025-08-14 | $93.66M 10-Q · filed 2025-08-14 | $139.45M derived: sum of 3 quarters · filed 2025-08-14 | $177.32M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $47.47M 10-Q · filed 2025-05-13 | $93.26M derived: sum of 2 quarters · filed 2025-05-13 | $131.13M derived: sum of 3 quarters · filed 2025-05-13 | $163.45M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $45.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $83.66M derived: sum of 2 quarters · filed 2025-03-13 | $115.98M derived: sum of 3 quarters · filed 2025-03-13 | $151.08M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $37.87M 10-Q · filed 2024-11-13 | $70.19M derived: sum of 2 quarters · filed 2024-11-13 | $105.28M 10-Q · filed 2024-11-13 | $141.05M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $32.33M 10-Q · filed 2024-08-12 | $67.42M 10-Q · filed 2024-08-12 | $103.19M derived: sum of 3 quarters · filed 2024-08-12 | $130.81M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $35.09M 10-Q · filed 2024-05-09 | $70.86M derived: sum of 2 quarters · filed 2024-05-09 | $98.48M derived: sum of 3 quarters · filed 2024-05-09 | $133.00M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $35.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $63.39M derived: sum of 2 quarters · filed 2024-03-15 | $97.91M derived: sum of 3 quarters · filed 2024-03-15 | $132.28M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $27.62M 10-Q · filed 2023-11-14 | $62.14M derived: sum of 2 quarters · filed 2023-11-14 | $96.51M 10-Q · filed 2023-11-14 | $125.24M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $34.52M 10-Q · filed 2023-08-10 | $68.88M 10-Q · filed 2023-08-10 | $97.62M derived: sum of 3 quarters · filed 2023-08-10 | $127.12M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $34.37M 10-Q · filed 2023-05-11 | $63.10M derived: sum of 2 quarters · filed 2023-05-11 | $92.60M derived: sum of 3 quarters · filed 2023-05-11 | $118.20M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $28.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $58.23M derived: sum of 2 quarters · filed 2023-03-14 | $83.83M derived: sum of 3 quarters · filed 2023-03-14 | $110.46M 10-K · filed 2023-03-14 | $110.89M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $29.50M 10-Q · filed 2022-11-10 | $29.50M 10-Q · filed 2021-11-10 | $55.10M derived: sum of 2 quarters · filed 2022-11-10 | $81.73M 10-Q · filed 2022-11-10 | $98.73M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $25.60M 10-Q · filed 2022-08-11 | $52.23M 10-Q · filed 2022-08-11 | $69.23M derived: sum of 3 quarters · filed 2022-08-11 | $82.75M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $26.63M 10-Q · filed 2022-05-12 | $43.63M derived: sum of 2 quarters · filed 2022-05-12 | $57.16M derived: sum of 3 quarters · filed 2022-05-12 | $84.85M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $17.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $30.53M derived: sum of 2 quarters · filed 2022-03-10 | $58.23M derived: sum of 3 quarters · filed 2022-03-10 | $78.12M 10-K · filed 2022-03-10 | $78.12M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $13.52M 10-Q · filed 2021-11-10 | $13.52M 10-Q · filed 2020-11-05 | $41.22M derived: sum of 2 quarters · filed 2021-11-10 | $61.11M 10-Q · filed 2021-11-10 | $61.11M 10-Q · filed 2020-11-05 | $73.50M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $27.70M 10-Q · filed 2021-08-11 | $27.70M 10-Q · filed 2020-08-06 | $47.59M 10-Q · filed 2021-08-11 | $47.59M 10-Q · filed 2020-08-06 | $59.97M derived: sum of 3 quarters · filed 2021-08-11 | $74.46M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $19.89M 10-Q · filed 2021-05-11 | $19.89M 10-Q · filed 2020-05-07 | $32.28M derived: sum of 2 quarters · filed 2021-05-11 | $46.76M derived: sum of 3 quarters · filed 2021-05-11 | $69.97M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $12.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $26.88M derived: sum of 2 quarters · filed 2021-03-11 | $50.08M derived: sum of 3 quarters · filed 2021-03-11 | $71.56M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $14.49M 10-Q · filed 2020-11-05 | $37.70M derived: sum of 2 quarters · filed 2020-11-05 | $59.17M 10-Q · filed 2020-11-05 | $79.32M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $23.21M 10-Q · filed 2020-08-06 | $44.68M 10-Q · filed 2020-08-06 | $64.83M derived: sum of 3 quarters · filed 2020-08-06 | $79.57M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $21.48M 10-Q · filed 2020-05-07 | $41.62M derived: sum of 2 quarters · filed 2020-05-07 | $56.36M derived: sum of 3 quarters · filed 2020-05-07 | $81.53M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $20.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $34.89M derived: sum of 2 quarters · filed 2020-03-11 | $60.05M derived: sum of 3 quarters · filed 2020-03-11 | $78.10M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $14.74M 10-Q · filed 2019-11-07 | $39.91M derived: sum of 2 quarters · filed 2019-11-07 | $57.96M 10-Q · filed 2019-11-07 | $66.32M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $25.17M 10-Q · filed 2019-08-07 | $43.22M 10-Q · filed 2019-08-07 | $51.58M derived: sum of 3 quarters · filed 2019-08-07 | $60.35M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $18.05M 10-Q · filed 2019-05-14 | $26.41M derived: sum of 2 quarters · filed 2019-05-14 | $35.18M derived: sum of 3 quarters · filed 2019-05-14 | $42.76M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $17.13M derived: sum of 2 quarters · filed 2019-03-26 | $24.71M derived: sum of 3 quarters · filed 2019-03-26 | $31.68M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $8.76M 10-Q · filed 2018-11-08 | $16.35M derived: sum of 2 quarters · filed 2018-11-08 | $23.32M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $7.59M 10-Q · filed 2018-08-08 | $14.56M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |